SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo« - Evogene

01/11/2022 | 12:33pm EDT

* Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health

Rehovot, Israel -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept (POC), Phase I clinical trial of Biomica's drug candidate BMC-128 in patients with Non-Small Cell Lung Cancer (NSCLC), Melanoma or Renal Cell Carcinoma (RCC), in combination with immune checkpoint inhibitor (ICI) immunotherapy (an anti-PD-1 agent).

Biomica has entered into a supply agreement for the utilization of Bristol Myers Squibb's (BMS) Opdivo® to evaluate the safety and tolerability of BMC-128 therapy in combination with nivolumab (Opdivo®), a human anti-PD-1 therapy, in multiple cancer indications.

The POC combination trial is designed to be a first-in-human (FIH) open-label study to evaluate the safety and tolerability of BMC-128 in combination with BMS' Opdivo® in patients with NSCLC, melanoma or RCC, clinical signals will be monitored as well. This study is expected to take place at Rambam Health Care Campus, as previously announced[1].

About BMC128:

BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene's MicroBoost AI platform.

Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.

Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a host's microbial community with individually selected, cultured bacteria.

About Biomica Ltd.:

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, please visit

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag Ltd. For more information, please visit

Forward Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. For example, Biomica and Evogene are using forward-looking statements in this press release when they discuss the development plans for, and the potential safety, tolerability and capabilities of, Biomica's BMC-128 drug candidate. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene's reports filed with the applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


Rivka Neufeld

Investor Relations and Public Relations Manager


T: +972-8-931-1940

US Investor Relations:

Joseph Green

Edison Group


T: +1 646-653-7030

Laine Yonker

Edison Group


T: +1 646-653-7035



(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.87% 76.14 Delayed Quote.22.12%
EVOGENE LTD. -3.58% 2.988 End-of-day quote.-44.41%
05/27U.S. Food and Drug Administration Approves Two Opdivo« (nivolumab)-Based Regimens as Fi..
05/27Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens
05/26Bristol-Myers Squibb Says Phase 2 Study Evaluating CAR T Cell Therapy for Lymphoma Show..
05/26Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Sho..
05/26Bristol-Myers Squibb Company Announces Results from Primary Analysis of PILOT, A Multic..
05/26Citigroup Adjusts Price Target on Bristol-Myers Squibb to $90 From $75, Reiterates Buy ..
05/26Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conf..
05/19Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treat..
05/19Bristol-Myers Squibb Company Presents Data At ASCO and EHA 2022 Highlight Progress in T..
05/18Purple Biotech Initiates Phase 2 Study of Combination Treatment for Pancreatic Cancer; ..
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2022 46 544 M - -
Net income 2022 7 451 M - -
Net Debt 2022 21 743 M - -
P/E ratio 2022 26,4x
Yield 2022 2,82%
Capitalization 162 B 162 B -
EV / Sales 2022 3,95x
EV / Sales 2023 3,58x
Nbr of Employees 32 200
Free-Float 72,8%
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 76,14 $
Average target price 78,69 $
Spread / Average Target 3,35%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Samit Hirawat Chief Medical Officer-Global Drug Development
Rupert J. Vessey Executive VP-Research & Early Development
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ROCHE HOLDING AG-13.00%281 098